These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16400314)

  • 1. Updates in multiple sclerosis and related disorders: highlights of the 57th Annual Meeting of the American Academy of Neurology, April 9-16, 2005, Miami Beach, FL.
    Cook SD
    Rev Neurol Dis; 2005; 2(3):138-43. PubMed ID: 16400314
    [No Abstract]   [Full Text] [Related]  

  • 2. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
    Berger T; Deisenhammer F
    N Engl J Med; 2005 Oct; 353(16):1744-6; author reply 1744-6. PubMed ID: 16236749
    [No Abstract]   [Full Text] [Related]  

  • 3. Quantitative risk-benefit analysis of natalizumab.
    Thompson JP; Noyes K; Dorsey ER; Schwid SR; Holloway RG
    Neurology; 2008 Jul; 71(5):357-64. PubMed ID: 18663181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating multiple sclerosis with natalizumab.
    Iaffaldano P; Lucchese G; Trojano M
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA.
    Tyler KL; Khalili K
    Rev Neurol Dis; 2005; 2(3):144-9. PubMed ID: 16400315
    [No Abstract]   [Full Text] [Related]  

  • 6. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 7. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
    Alvarez-Cermeño JC; Masjuan J; Villar LM
    N Engl J Med; 2005 Oct; 353(16):1744-6; author reply 1744-6. PubMed ID: 16240475
    [No Abstract]   [Full Text] [Related]  

  • 8. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
    Kleinschmidt-DeMasters BK; Tyler KL
    N Engl J Med; 2005 Jul; 353(4):369-74. PubMed ID: 15947079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab.
    Hartung HP
    Lancet Neurol; 2009 Jan; 8(1):28-31. PubMed ID: 19081511
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.
    Fox RJ; Bethoux F; Goldman MD; Cohen JA
    Cleve Clin J Med; 2006 Jan; 73(1):91-102. PubMed ID: 16444920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
    [No Abstract]   [Full Text] [Related]  

  • 14. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
    Dorsey ER; Thompson JP; Noyes K; Dick AW; Holloway RG; Schwid SR
    Neurology; 2007 May; 68(18):1524-8. PubMed ID: 17470756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PML risk and natalizumab: more questions than answers.
    Ransohoff RM
    Lancet Neurol; 2010 Mar; 9(3):231-3. PubMed ID: 20117056
    [No Abstract]   [Full Text] [Related]  

  • 17. [Optic neuromyelitis. Main differences with multiple sclerosis].
    Lopategui Cabezas I; Cervantes Llano M; Pentón Rol G
    An Med Interna; 2008 Jun; 25(6):294-6. PubMed ID: 19295979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons for clinical trials from natalizumab in multiple sclerosis.
    Chaudhuri A
    BMJ; 2006 Feb; 332(7538):416-9. PubMed ID: 16484271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency of antibody therapy in demyelinating diseases.
    Akaishi T; Nakashima I
    Int Immunol; 2017 Jul; 29(7):327-335. PubMed ID: 28910968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The return of natalizumab: weighing benefit against risk.
    Goodin D
    Lancet Neurol; 2006 May; 5(5):375-7. PubMed ID: 16632301
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.